Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 601 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 37 |
| 602 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 57 |
| 603 | Apheresis | Allogeneic | Thalassemia Major | Hematology | 2026 | Standard Therapy | Turkey | 1 |
| 604 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 59 |
| 605 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Switzerland | 65 |
| 606 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 28 |
| 607 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Estonia | 67 |
| 608 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Czechia | 28 |
| 609 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 71 |
| 610 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 73 |
| 611 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 73 |
| 612 | Apheresis | Allogeneic | Acute Myeloblastic Leukemia | Hematology | 2026 | Standard Therapy | Romania | 62 |
| 613 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 62 |
| 614 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | USA | 52 |
| 615 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 71 |
| 616 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Spain | 48 |
| 617 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | USA | 59 |
| 618 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 52 |
| 619 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 43 |
| 620 | Apheresis | Allogeneic | Akut Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Turkey | 48 |
| 621 | Apheresis | Allogeneic | Chronic myelomonocytic leukemia | Hematology | 2026 | Standard Therapy | Finland | 16 |
| 622 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 30 |
| 623 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | Germany | 72 |
| 624 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 50 |
| 625 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 70 |
| 626 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Spain | 45 |
| 627 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 75 |
| 628 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 39 |
| 629 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 32 |
| 630 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Argentina | 34 |
| 631 | Apheresis | Allogeneic | Other Malignancy, Specify | Hematology | 2026 | Standard Therapy | USA | 68 |
| 632 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Switzerland | 63 |
| 633 | Apheresis | Allogeneic | T-Cell Non-Hodgkin lymphoma | Hematology | 2026 | Standard Therapy | Argentina | 70 |
| 634 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Czechia | 52 |
| 635 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | France | 62 |
| 636 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 20 |
| 637 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 53 |
| 638 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | United Kingdom | 56 |
| 639 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 71 |
| 640 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 54 |
| 641 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Hungary | 36 |
| 642 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | France | 47 |
| 643 | Apheresis | Autologus | Diffuse Large B-Cell Lymphoma | hematology | 2026 | Standard Therapy | Germany | 65 |
| 644 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 59 |
| 645 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 59 |
| 646 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 59 |
| 647 | Apheresis | Autologus | Diffuse Large B-Cell Lymphoma | hematology | 2026 | Standard Therapy | Germany | 63 |
| 648 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 37 |
| 649 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 61 |
| 650 | Apheresis | Autologus | Multiple Myeloma | hematology | 2026 | Standard Therapy | Germany | 63 |
| 651 | Apheresis | Allogeneic | CMMOL-AML | hematology | 2026 | Standard Therapy | Hungary | 47 |
| 652 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Spain | 52 |
| 653 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 53 |
| 654 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Poland | 61 |
| 655 | Apheresis | Allogeneic | Other Non-Malignant Disease | hematology | 2026 | Standard Therapy | USA | 67 |
| 656 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Germany | 3 |
| 657 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 38 |
| 658 | Apheresis | Allogeneic | Prolymphocytic Leukemia | hematology | 2026 | Standard Therapy | United Kingdom | 60 |
| 659 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Poland | 70 |
| 660 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 48 |
| 661 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | France | 60 |
| 662 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | USA | 51 |
| 663 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Chile | 6 |
| 664 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 56 |
| 665 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | USA | 69 |
| 666 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | USA | 41 |
| 667 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | hematology | 2026 | Standard Therapy | United Kingdom | 66 |
| 668 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Italy | 65 |
| 669 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | hematology | 2026 | Standard Therapy | Germany | 49 |
| 670 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | USA | 76 |
| 671 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Italy | 61 |
| 672 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Poland | 4 |
| 673 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | USA | 65 |
| 674 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Poland | 59 |
| 675 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | hematology | 2026 | Standard Therapy | Germany | 50 |
| 676 | Apheresis | Allogeneic | Myelodysplastic/Myeloproliferative Neoplasms | hematology | 2026 | Standard Therapy | Poland | 69 |
| 677 | Apheresis | Allogeneic | Hodgkin Lymphoma | hematology | 2026 | Standard Therapy | USA | 48 |
| 678 | Apheresis | Allogeneic | Prolymphocytic Leukemia | hematology | 2026 | Standard Therapy | USA | 71 |
| 679 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | United Kingdom | 55 |
| 680 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 59 |
| 681 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | United Kingdom | 62 |
| 682 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | France | 65 |
| 683 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Germany | 75 |
| 684 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 57 |
| 685 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 72 |
| 686 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 32 |
| 687 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Bulgaria | 63 |
| 688 | Apheresis | Allogeneic | Myelofibrosis | hematology | 2026 | Standard Therapy | Hungary | 52 |
| 689 | Apheresis | Allogeneic | Myelodysplastic Syndrome | hematology | 2026 | Standard Therapy | Germany | 64 |
| 690 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | hematology | 2026 | Standard Therapy | Poland | 24 |
| 691 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Germany | 59 |
| 692 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | hematology | 2026 | Standard Therapy | Belgium | 65 |
| 693 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | hematology | 2026 | Standard Therapy | USA | 65 |
| 694 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | hematology | 2026 | Standard Therapy | USA | 47 |
| 695 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | hematology | 2026 | Standard Therapy | Sweden | 21 |
| 696 | Apheresis | Autologous | Multiple Myeloma | hematology | 2026 | Standard Therapy | Portugal | 57 |
| 697 | Apheresis | Autologous | Multiple Myeloma | hematology | 2026 | Standard Therapy | Portugal | 68 |
| 698 | Cord Tissue | Allogeneic – Related | Chronic renal disease | Endocrinology | 2025 | Experimental Therapy | Romania | 50 |
| 699 | Cord Tissue | Allogeneic – Related | Autism | Neurology | 2025 | Experimental Therapy | Romania | 6 |
| 700 | Cord Tissue | Autologous | Autism | Neurology | 2025 | Experimental Therapy | Romania | 6 |